| Mesangial cellularity | Glomerulosclerosis | Tubule‒interstitial damage | ||||||
---|---|---|---|---|---|---|---|---|---|
 | Mild | Severe | P | Mild | Severe | P | Mild | Severe | P |
Number of patients | 64 | 34 | Â | 81 | 17 | Â | 78 | 20 | Â |
Age, years | 9.5 [2.8‒15] | 9.8 [3.9‒15] | NS | 9.1 [2.8‒15] | 10.4 [4.1‒14.3] | NS | 8.5 [2.8‒15] | 11.7 [3.1‒15] | .001 |
Sex (male/ female) | 36/28 | 22/12 | NS | 48/33 | 10/7 | NS | 43/35 | 15/5 | NS |
Body weight, kg | 30 [14‒71] | 31.5 [15‒65] | NS | 27.5 [14‒71 | 32 [15.5‒57] | NS | 27 [14‒65] | 37 [17‒71] | .003 |
Histological diagnosis, n (%) | |||||||||
 IgAN | 20 (31) | 20 (59) | .008 | 31 (38) | 9 (53) | NS | 29 (37) | 11 (55) | NS |
 IgMN | 28 (44) | 9 (26) | NS | 32 (40) | 5 (29) | NS | 32 (41) | 5 (25) | NS |
MesPGN(IgA‒ IgM‒) | 16 (25) | 5 (15) | NS | 18 (22) | 3 (18) | NS | 17 (22) | 4 (20) | NS |
Clinical features* n (%) | |||||||||
 Mild | 55 (86) | 21 (62) | .006 | 65 (80) | 11 (65) | NS | 61 (78) | 15 (75) | NS |
 Severe | 9 (14) | 13 (38) | .006 | 16 (20) | 6 (35) | NS | 17 (22) | 5 (25) | NS |
Hematuria n (%) | |||||||||
 5‒10RBC/HPF | 11 (17) | 2 (6) | NS | 12 (15) | 1 (6) | NS | 10 (13) | 3 (15) | NS |
 10‒30RBC/HPF | 36 (56) | 23 (68) | NS | 47 (58) | 12 (71) | NS | 43 (55) | 16 (80) | NS |
 > 30RBC/HPF | 16 (25) | 8 (24) | NS | 21 (26) | 3 (18) | NS | 23 (29) | 1 (5) | .021 |
Proteinuria, n (%) | |||||||||
 > 4mg/m2/h | 29 (45) | 27 (79) | .001 | 42 (52) | 14 (82) | .021 | 44 (56) | 12 (60) | NS |
 > 40mg/m2/h | 11 (17) | 17 (50) | .001 | 18 (22) | 10 (59) | .002 | 19 (24) | 9 (45) | NS |
Prednisone, n (%) | 18 (28) | 21 (62) | .001 | 27 (33) | 12 (71) | .004 | 28 (36) | 11 (55) | NS |
Cyclophosphamide | 4 (6) | 6 (18) | NS | 5 (6) | 5 (29) | .013 | 6 (8) | 4 (20) | NS |